Navigating the Shift in Microbial Control: Understanding USP <1110>

May 5
3 min read

Updated: Jun 6

If you’re a Quality Director, Sterility Assurance Lead, or Qualified Person in a regulated pharmaceutical or biologics manufacturing facility, there’s a quiet shift happening in your regulatory landscape that is already putting companies on the FDA’s radar.

That shift?

The updated USP <1110>: Sampling for Microbiological Control.

If your microbial monitoring program hasn’t been updated with this in mind, you’re already behind.

Why You Need to Adapt Your Environmental Monitoring

For years, many facilities have relied on static, one-size-fits-all environmental monitoring (EM) programs. These programs included fixed sampling points, predefined frequencies, and legacy SOPs that were considered “compliant enough” to keep the company under the radar.

But that’s no longer sufficient.

The revised USP <1110> aligns closely with EU Annex 1 (2022) and ICH Q9(R1). It emphasizes that microbial control must stem from a risk-based rationale, not just routine practices. Sampling locations, frequencies, and methods now have to reflect product-specific risks and facility-specific process understanding.

The Implications for Your Operations

What does this mean for you? Here are several key points to consider:

You must justify your sampling strategy using science and risk.
You need a Contamination Control Strategy (CCS) that integrates with your EM plan.
Train your team on the “why” behind microbial control, not just the “how.”

Failure to comply invites 483 observations, recalls, or worse: product contamination events that could seriously affect patient safety.

Addressing Compliance Gaps

You may have attempted to patch these compliance gaps already:

Updating SOPs for EM locations without conducting a risk assessment.
Engaging generalist consultants who provide generic templates.
Advising staff to "sample more" during excursions without investigating root causes.

While these efforts may seem beneficial, they are inadequate.

Regulators expect holistic microbial control programs that provide a traceable logic from Contamination Control Strategy to Environmental Monitoring Plan, Risk Assessment, and Action.

Anything less simply ticks boxes.

The Evolving Expectations of Regulators

Regulatory authorities like the FDA and EMA are now explicitly looking for specific criteria, including:

Justification for EM sampling points and frequency.
Demonstration of CCS alignment with manufacturing risks.
Appropriate reactions to microbial excursion trends.

They are not just asking, “Did you monitor?” They want to know: “Did you monitor the right places, at the right times, for the right reasons and act accordingly?”

What You Really Want for Your Microbial Program

You want confidence that your microbial control program will withstand scrutiny during the most intense inspections.

Your goals should include:

A Contamination Control Strategy that aligns with Annex 1 and USP <1110>.
A scientifically justified EM program that’s not only defensible but also adaptable.
A well-trained team that understands why microbial control is crucial and is not limited to simply following SOPs.
A way to implement all this effectively, without disrupting production or straining resources.

The CCEP Advantage with Pharmalliance Consulting Ltd

At Pharmalliance Consulting Ltd, we specialize in one area: Contamination Control.

We provide expert implementation of contamination prevention programs in sterile and non-sterile environments. Our signature offering, the Contamination Control Excellence Program (CCEP), delivers exactly what companies like yours need.

✅ Creation and Deployment of Your Contamination Control Strategy

Most organizations struggle to create a living, adaptable CCS. We don’t. CCEP includes comprehensive CCS framework templates, implementation plans, and evaluation tools—each pre-populated and validated to pass regulatory scrutiny.

✅ Cross-Functional Team Training on Contamination Control

Your operators, engineers, and QA staff will fully understand contamination control rather than merely following instructions. Our training includes scientific principles, real-world case studies, and techniques to recognize and prevent risks before they escalate. Our 35 online modules give you everything you need to Educate, Execute, and Elevate your contamination control efforts.

✅ Full Regulatory Alignment — Fast

We provide this transformation within just 8 to 12 weeks. Our approach has successfully helped ATMPs, CDMOs, and global pharmaceutical manufacturers achieve zero inspection findings related to CCS.

What Sets Pharmalliance Apart?

We’re not just another GMP consultancy. Here’s what makes us different:

🧪 Contamination control is our singular focus. We immerse ourselves in sterile manufacturing, cleanroom risk, and CCS frameworks.
📚 Our training resources are grounded in EU Annex 1, USP <1110>, PDA TR90, and FDA guidance—no guesswork involved.
💻 Our digital-first, outcome-focused approach allows the CCEP to be available online, onsite, or in hybrid formats, encompassing over 35 modular topics with expert coaching.